BioHemp International, Inc. focuses on operating in the fast-growing consumer hemp and cannabidiol (CBD) market through a strategic rollup of CBD distributors. More Details
Weak fundamentals or lack of information.
Share Price & News
How has BioHemp International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BKIT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BKIT underperformed the US Healthcare industry which returned 17.2% over the past year.
Return vs Market: BKIT underperformed the US Market which returned 10.9% over the past year.
Price Volatility Vs. Market
How volatile is BioHemp International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is BioHemp International undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether BioHemp International is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BioHemp International has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of BKIT's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through BioHemp International regulatory filings here.
- Explore potentially undervalued companies in the Healthcare industry.
How is BioHemp International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioHemp International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of BKIT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access BioHemp International's filings and announcementshere.
- Explore growth companies in the Healthcare industry.
How has BioHemp International performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: BKIT is currently unprofitable.
Growing Profit Margin: BKIT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BKIT's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BKIT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BKIT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).
Return on Equity
High ROE: BKIT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is BioHemp International's financial position?
Financial Position Analysis
Short Term Liabilities: BKIT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BKIT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BKIT has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BKIT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if BKIT has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BKIT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is BioHemp International current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BKIT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BKIT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BKIT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BKIT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BKIT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Daniel Blum (30 yo)
Mr. Daniel Blum serves as the President, Chief Executive Officer, Secretary, and Treasurer of BioHemp International, Inc. (formerly known as Blake Insomnia Therapeutics, Inc.) since May 15, 2019 and serves ...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BioHemp International, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: BioHemp International, Inc.
- Ticker: BKIT
- Exchange: OTCPK
- Founded: 2012
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: US$201.954k
- Shares outstanding: 28.85m
- Website: https://www.biohempinternational.com
Number of Employees
- BioHemp International, Inc.
- 244, 5th Avenue
- Suite A-154
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BKIT||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Sep 2013|
BioHemp International, Inc. focuses on operating in the fast-growing consumer hemp and cannabidiol (CBD) market through a strategic rollup of CBD distributors. It focuses on the creation of distribution pl ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/26 06:23|
|End of Day Share Price||2020/09/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.